Hemogenyx Pharmaceuticals Plc
HOPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $800 | $0 | $2,600 | $284 |
| Gross Profit | -$800 | $0 | -$2,600 | -$284 |
| % Margin | – | – | – | – |
| R&D Expenses | $237 | $0 | $0 | $0 |
| G&A Expenses | $4,738 | $5 | $942 | $1,397 |
| SG&A Expenses | $4,738 | $5 | $942 | $1,397 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,390 | $1 | $0 | $0 |
| Operating Expenses | $6,365 | $6 | $2,931 | $2,547 |
| Operating Income | -$7,165 | -$6 | $3,998 | -$2,703 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $127 | -$0 | $11 | -$2,406 |
| Pre-Tax Income | -$7,038 | -$7 | -$3,987 | -$5,108 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,619 | -$7 | -$3,979 | -$5,099 |
| % Margin | – | – | – | – |
| EPS | -2.13 | -2.37 | -1.62 | -2.64 |
| % Growth | 10.1% | -46.3% | 38.6% | – |
| EPS Diluted | -2.13 | -2.37 | -1.62 | -2.64 |
| Weighted Avg Shares Out | 3,301 | 3 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3,301 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29 | $0 | $11 | $18 |
| Interest Expense | $340 | $0 | $0 | $2,595 |
| Depreciation & Amortization | $231 | $0 | $564 | $126 |
| EBITDA | -$5,147 | -$5 | -$5,441 | -$2,576 |
| % Margin | – | – | – | – |